Iantrek’s Bio-Interventional Technology Shows Positive Glaucoma Surgery Results

Iantrek Corporation has released promising results from its two-year clinical study on bio-reinforced cyclodialysis technology, highlighting its effectiveness in enhancing uveoscleral outflow for glaucoma patients. Published in Ophthalmology Science, the study supports the safety and efficacy of this innovative bio-interventional approach for individuals undergoing cataract surgery.

Study Findings

The clinical study assessed the impact of Iantrek’s bio-interventional technology in open-angle glaucoma patients. Key findings include:

       • 74% of treated eyes achieved a ≥20% reduction in intraocular pressure (IOP) at two years while maintaining the same or fewer glaucoma medications.

       • Mean IOP reduction of 34% was observed.

       • IOP-lowering medication use decreased by over 60%.

       • No serious ocular adverse events were reported throughout the study.

Dr. Robert N. Weinreb, Distinguished Professor and Chair of Ophthalmology at the University of California, San Diego, emphasized the breakthrough nature of this approach, stating:

“This study highlights a meaningful advancement in glaucoma surgery by safely and effectively targeting the uveoscleral pathway through a minimally invasive, bio-interventional approach. This represents a groundbreaking, hardware-free solution using next-generation, homologous bio-tissue materials for superior biocompatibility.”

Validation and Industry Recognition

The study’s findings were reinforced by a recent presentation at the 2025 American Glaucoma Society Annual Meeting, where Dr. Leon W. Herndon of Duke University shared two-year results from the CREST study, the largest surgical glaucoma cohort to date. The results demonstrated sustained IOP reduction with a favorable safety profile, further validating Iantrek’s technology.

Commercialization and Future Plans

Iantrek holds the distinction of being the only company with FDA-approved technology specifically designed to surgically enhance uveoscleral outflow pathways for lowering IOP. The company has announced plans for broad commercialization later this year, aiming to integrate its technology into both standalone and combination ophthalmic procedures.

Conclusion

With strong clinical validation and regulatory approval, Iantrek’s bio-interventional technology marks a significant step forward in glaucoma management. By providing a hardware-free, biocompatible solution, this approach has the potential to reshape surgical glaucoma treatments and improve patient outcomes worldwide.